• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark

    Reed-Lane Facility Virtual Tour
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    Adare Pharma Solutions

    Cytovance Biologics

    Alcami

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    PCI Pharma Services

    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    01 Pfizer, Inc.

    ...

    01	Pfizer, Inc.
    Related CONTENT
    • Strata Oncology Unveils Strata PATH Trial
    • Reshaping the Pharmaceutical Supply Chain
    • Spark Therapeutics Appoints CTO
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    07.15.19
    Headquarters: New York, NY
    twitter.com@pfizer_news
    www.pfizer.com



    Headcount: 92,400
    Year Established: 1849
    Revenues:  $53,647  (+2%)
    Net Income:  $11,153  (-48%)
    R&D:  $8,006  (+4%)

    TOP SELLING DRUGS
    Drug Indication 2018 (+/-%)
    Prevnar 13 pneumoccal vaccine $5,802 4%
    Lyrica epilepsy, neuropathy $4,970 -2%
    Ibrance cancer $4,118 32%
    Enbrel rheumatoid arthritis $2,112 -14%
    Lipitor cholesterol $2,062 8%
    Xeljanz arthritis $1,774 32%
    Chantix smoking cessation $1,085 9%
    Sutent cancer $1,049 -3%
    Norvasc hypertention $1,024 11%
    Premarin menopause $832 -15%


    In 2018, Pfizer reported revenues of $53,647 billion, an increase of two percent, as several of its biggest-selling medicines and vaccines continued to grow, including Ibrance, Eliquis, Xeljanz and Prevnar 13. Pfizer also reported growth in emerging markets and in biosimilars, which helped to absorb $1.7 billion in lost revenue because of products that recently lost marketing exclusivity. Eight billion dollars was invested during the year in research and development (R&D).

    During the year, Pfizer unveiled plans to reorganize into three businesses, which became effective at the beginning of the company’s 2019 fiscal year, and are Pfizer Biopharmaceuticals Group, that now includes biosimilars and a new Hospital business unit for anti-infectives and sterile injectables; Upjohn, an off-patent branded and generic medicines business based in China that is bringing 20 of its most iconic brands to more than 100 markets around the world; and a Consumer Healthcare business aligned with the growing trend of consumers taking their health into their own hands.

    Also on the consumer side of the business, at the end of the year Pfizer and GlaxoSmithKline entered a joint venture to create a global consumer healthcare company. The deal calls for Pfizer contributing its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business. The 2017 global sales for the combined business were approximately $12.7 billion. The deal is expected to close in the second half of 2019.

    The joint venture will be a category leader in pain relief, respiratory, vitamin and mineral supplements, digestive health, skin health and therapeutic oral health. It’s expected to be among the largest consumer healthcare players in key geographies, including the U.S., Europe, China, India and Australasia. The joint venture will operate globally under the GSK Consumer Healthcare name. Following the integration, GSK intends to separate the joint venture as an independent company.

    As we moved into 2019, it was announced that Dr. Albert Bourla, chief operating officer at the time, would be taking over the reins of the stripped down Pfizer organization as its new chief executive officer, succeeding Ian Read. Under Mr. Read, Pfizer received 30 FDA approvals and amassed a pipeline with the potential for approximately 25-30 approvals through 2022, of which as many as 15 have the potential to be blockbusters.

    Sterile manufacturing investment
    In terms of growth, Pfizer is investing $465 million to expand its U.S. manufacturing with technically advanced sterile injectable pharmaceutical production facilities in Portage, MI, which will create approximately 450 new jobs over the next several years. Known as Modular Aseptic Processing (MAP), the new 400,000 square foot production facility expands Pfizer’s presence in Portage, located in Kalamazoo County, where the company now employs more than 2,200 people at one of its largest plants.

    MAP will incorporate technically advanced aseptic manufacturing equipment, systems and design, including multiple, self-contained modular manufacturing lines. This allows the manufacturing line in each module to be entirely separate from all other manufacturing lines. Construction is expected to be completed in 2021. After the facility is validated by regulatory agencies, production should begin in 2024.

    The investment is part of Pfizer’s overall plan to invest approximately $5 billion in U.S.-based capital projects as a result of the enactment of the Tax Cuts and Jobs Act. During the next six years, the company expects to invest approximately $1.1 billion in Kalamazoo County, which is in addition to the $1 billion it has invested in the site over the past decade.

    The Portage site is a primary global supplier of sterile injectable, liquids and semi-solid medicines, and active pharmaceutical ingredients (APIs), producing more than 150 products. Its biggest product is Solu-Medrol, a widely used injectable anti-inflammatory medicine.

    Cancer research collaborations
    Pfizer remained active during the year on the cancer research front. It inked a deal worth up to $520 million with Kineta Immuno-Oncology (KIO), to develop RIG-I agonist immunotherapies for the treatment of cancer.

    Leap Therapeutics entered into a collaboration with Pfizer and Merck KGaA to evaluate Leap’s GITR agonist, TRX518, in combination with avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, and chemotherapy. Avelumab has received accelerated approval by the FDA for the treatment of patients with metastatic Merkel cell carcinoma (MCC) and previously treated patients with locally advanced or metastatic urothelial carcinoma (mUC), and is under further clinical evaluation across a range of tumor types under a global strategic alliance between Merck KGaA and Pfizer.

    Daiichi Sankyo also entered into a clinical trial collaboration agreement with Pfizer and Merck KGaA to evaluate the combination of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), in combination with the checkpoint inhibitor avelumab and/or an investigational Merck KGaA DNA damage response (DDR) inhibitor, in patients with HER2 expressing or mutated solid tumors. 

    A separate research collaboration to conduct preclinical studies evaluating [fam-] trastuzumab deruxtecan in combination with avelumab, the DDR inhibitor and other investigational compounds in Merck KGaA’s and Pfizer’s pipelines is also underway.

    Aside from cancer, during the year Pfizer also signed a $425 million flu vaccine deal with BioNTech AG, a biotech focused on precise immunotherapies for the treatment of cancer and infectious disease. The multi-year R&D collaboration’s goal is to develop mRNA-based vaccines for the prevention of influenza (flu). 
    Related Searches
    • headquarters
    • glaxosmithkline
    • sterile manufacturing
    • immuno-oncology
    Suggested For You
    Strata Oncology Unveils Strata PATH Trial Strata Oncology Unveils Strata PATH Trial
    Reshaping the Pharmaceutical Supply Chain Reshaping the Pharmaceutical Supply Chain
    Spark Therapeutics Appoints CTO Spark Therapeutics Appoints CTO
    Ashfield Engage, Popit Form Digital Monitoring Collaboration Ashfield Engage, Popit Form Digital Monitoring Collaboration
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    Pfizer Partners with Medicines Manufacturing Innovation Center Pfizer Partners with Medicines Manufacturing Innovation Center
    Pfizer Selects Seven Bridges to Support RNA Sequencing Data Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    Pfizer, BioNTech To Supply 200M More Vax Doses to EU Pfizer, BioNTech To Supply 200M More Vax Doses to EU
    Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine
    Pfizer Pfizer's 4Q Revenues up 12%
    Inside a Vaccine Trial Inside a Vaccine Trial
    Imcyse, Pfizer Enter Autoimmune Research Alliance Imcyse, Pfizer Enter Autoimmune Research Alliance
    Novartis Inks Contract Manufacturing Deal for Pfizer-BioNTech COVID-19 Vaccine Novartis Inks Contract Manufacturing Deal for Pfizer-BioNTech COVID-19 Vaccine
    The State of Clinical Trial Technology The State of Clinical Trial Technology
    Pfizer, BioNTech Enter Vax Pact with COVAX  Pfizer, BioNTech Enter Vax Pact with COVAX

    Related Top Companies Report

    • 25 CSL Behring

      25 CSL Behring

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 22 Astellas

      22 Astellas

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 21 Biogen

      21 Biogen

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20


    • 12 Amgen

      12 Amgen

      ...
      Tim Wright, Editor, Contract Pharma 07.20.20

    • 13 Gilead Sciences

      13 Gilead Sciences

      ...
      Kristin Brooks, Managing Editor 07.15.20

    • 10 Bristol-Myers Squibb

      10 Bristol-Myers Squibb

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.15.20


    • 03 Novartis

      03 Novartis

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 02 Roche

      02 Roche

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 09 Takeda

      09 Takeda

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 01 Pfizer, Inc.

      01 Pfizer, Inc.

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • The 2020 Top 25 Pharma and Biopharma Companies

      The 2020 Top 25 Pharma and Biopharma Companies

      Top 25 Pharma and Biopharma Companies (Based on 2019 Pharma/Biopharma Sales, in $U.S. Millions)
      Contract Pharma Staff 07.15.20

    • 08 GlaxoSmithKline

      08 GlaxoSmithKline

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 07 AbbVie

      07 AbbVie

      ...
      Kristin Brooks , Managing Editor, Contract Pharma 07.15.20

    • 06 Sanofi

      06 Sanofi

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 05 Merck

      05 Merck

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    Trending
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Reed-Lane Facility Virtual Tour
    Breaking News
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • Aptamer Extends Collaboration with AstraZeneca
    • Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Thymoquinone Inhibits Viral Infection in In Vitro Settings, New Study Finds
    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President and COO
    Ashland Completes Expansion and Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex CFO Announces Retirement
    New AI-Based Tool Developed for Coronary Artery Analysis, Intervention Planning
    First Reported Use of Pulse Biosciences' CellFX System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AGC Biologics Expands Cell and Gene Facility in Italy
    Celonic to Boost Cell & Gene Therapy Production
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Ulta Beauty Opens in Herald Square
    Elizabeth Arden Taps Sui He as Global Brand Ambassador
    Natura &Co Outperforms the Global Market in Q4 2020
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Indie Beauty Innovators Wanted
    Cosmetic Chemists Seek Mentors
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Arjobex America welcomes Maggie Naberezny to sales team
    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Bioventus Appoints Managing Director, China and Asia Pacific
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login